Special Issue "Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development"
Deadline for manuscript submissions: 30 April 2024 | Viewed by 7843
Interests: SARS-CoV-2; HIV-1; HPV; vaccine development; vaccine evaluation; immune response; neutralizing antibody; standardization of assay
The COVID-19 pandemic has been ongoing for more than two years, killing more than 6.5 million people and having an unimaginable impact on people’s lives. Safe, effective, affordable and accessible vaccines are considered an important weapon to end the outbreak. Neutralizing antibodies are important indicators for the evaluation of the effectiveness of SARS-CoV-2 vaccines. Standardized in vitro potency methods are urgently needed to evaluate antiviral products in both pre-clinical and clinical phases. In addition, the detection of neutralizing antibodies against SARS-CoV-2 would be helpful to understand the status of the protective immune response among COVID-19 patients and asymptomatic cases. At present, there are many methods for detecting SARS-CoV-2 neutralizing antibodies, including culture live virus neutralization method, recombinant replication virus neutralization method, pseudotyped virus neutralization method, and competition inhibition neutralization antibody detection method. Even if the same type of method is used, specific operations in different laboratories can lead to differences in results. As a result, the neutralizing antibody test results of different vaccines are incomparable, meaning that the immunogenicity of different vaccines cannot be compared horizontally.
To achieve a more holistic understanding of recent scientific knowledge and current trends in SARS-CoV-2 neutralization assay and vaccine development, this Special issue is focused on the recent scientific and technical progresses made in this field. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: (i) recent advances in novel neutralization assay development, (ii) standardization and comparison of different SARS-CoV-2 neutralization assays, (iii) comparison of neutralizing antibody responses induced by different vaccines, and (iv) correlates of protection.
I look forward to receiving your contributions.
Dr. Jianhui Nie
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neutralizing antibody
- correlation of protection